Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor
- 2 October 2012
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 20 (2), 593-599
- https://doi.org/10.1245/s10434-012-2682-y
Abstract
The immune system has been shown to play an important role in gastrointestinal stromal tumor (GIST). The neutrophil-to-lymphocyte ratio (NLR) in blood is an easily assessable parameter of systemic inflammatory response. The aim of this study was to determine whether the NLR is prognostic in GIST.Keywords
This publication has 34 references indexed in Scilit:
- The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of MalignancyAnnual Review of Medicine, 2012
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaEuropean Journal Of Cancer, 2012
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European regionBritish Journal of Cancer, 2010
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal Of Cancer, 2009
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998